EL20, a tetracaine derivative and RYR2 inhibitor, decreased spark activity in iPSC-CMs of a CPVT patient harbouring a RYR2 (p.(Arg176Gln)) mutation without negatively affecting the Ca2+ transient amplitude [24]. This evidence concerns the gene RYR2 and catecholaminergic polymorphic ventricular tachycardia.